ℹ️ No matches surfaced in the limited public sources we cover (sanctions, screening, insolvency, control). This is an automated indicator — not an exhaustive check, a credit decision, or a guarantee, and absence of a match does not mean none exists. Verify against the official register.
IPRASENSE SAS
Simplified joint-stock company (SAS) · RC 798503728 · Active since 2013
Overview
IPRASENSE SAS is a simplified joint-stock company (sas) registered in France, since 2013. The company operates in the other professional & technical sector. With reported revenue of 367K EUR in 2023. Its TraceComp score of 71 (B+) indicates moderate risk with some areas to watch. With 12 years of operations, the company has an established track record in its market.
Company Information
- Registration Number
- 798503728
- Legal Form
- Simplified joint-stock company (SAS)
- Registered
- 2013-11-08
Financial Profile
Latest filed accounts: FY 2023 · most recent available in public filings
Multi-year financials & ratios
5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Officers & Management
3 officers/directors on file — names, roles, appointment & resignation dates.
| Name | Role | Status |
|---|---|---|
| G•••••• J•••••• E•••••• | Officer | Current |
| D•••• J••••• S•••••• | Officer | Current |
| T•••••• J•••••• P••••• | Officer | Current |
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
EU Funding
EU-funded innovation. Participated in 2 EU research projects, receiving €369,750 in EU contributions (CORDIS — Horizon Europe / Horizon 2020).
Source: CORDIS (EU Open Data, CC-BY). Cumulative EC contribution across the company’s projects.
Patent Portfolio
Active patent holder. 5 patents · 5 active · 5 granted in the USPTO/EPO record.
See full patent portfolio — most-cited inventions & inventors →
Source: USPTO / EPO open patent data. Objective bibliographic counts.
Risk Signals
No adverse legal events have been recorded for this company.
- Revenue down 33% year-on-year
- Net loss reported in FY 2023
- Altman Z-Score in the distress zone — elevated insolvency risk on the model
Data Sources & Freshness
Data sourced from: bulk register.